샘플 요청 목록

 카트 문의
시장보고서
상품코드
1757940

세계의 애디슨병 치료제 시장

Addisons Disease Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 278 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 애디슨병 치료제 시장은 2030년까지 9억 4,830만 달러에 달할 전망

2024년에 6억 8,140만 달러로 추정되는 세계의 애디슨병 치료제 시장은 2024-2030년의 분석 기간에 CAGR 5.7%로 성장하며, 2030년에는 9억 4,830만 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 경구약은 CAGR 6.6%를 기록하며, 분석 기간 종료시에는 6억 6,140만 달러에 달할 것으로 예측됩니다. 비경구약 부문은 분석 기간 중 CAGR 3.7%의 성장이 전망됩니다.

미국 시장은 1억 8,570만 달러로 추정, 중국은 CAGR 9.1%로 성장 예측

미국의 애디슨병 치료제 시장은 2024년에 1억 8,570만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2024-2030년의 분석 기간에 CAGR 9.1%로 추이하며, 2030년에는 1억 9,320만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.7%와 5.6%로 예측됩니다. 유럽에서는 독일이 CAGR 3.7%로 성장할 것으로 예측됩니다.

세계의 애디슨병 치료제 시장 - 주요 동향과 촉진요인 정리

애디슨병 치료제가 내분비학, 희귀질환 관리, 호르몬 대체 혁신 분야에서 전략적 중요성이 커지고 있는 이유는 무엇인가?

애디슨병(원발성 부신 기능 부전)은 부신이 충분한 코티솔과 알도스테론을 생산하지 못하는 것이 특징인 희귀 내분비 질환입니다. 이 호르몬 결핍은 피로, 체중 감소, 저혈압, 색소침착 등의 증상을 유발합니다. 적절한 치료를 받지 않으면 환자는 특히 스트레스나 질병을 겪을 때 생명을 위협하는 부신기능부전증에 걸릴 위험이 있습니다.

애디슨병이 환자의 삶의 질에 미치는 영향과 심각한 합병증의 가능성에 대한 인식이 높아지면서 효과적인 치료 전략의 필요성이 강조되고 있습니다. 진단 기술의 발전으로 조기 발견이 가능해졌고, 현재 진행 중인 호르몬 대체요법에 대한 연구는 자연의 호르몬 리듬을 더 잘 모방하여 환자의 예후를 개선하는 것을 목표로 하고 있습니다.

서방형 제제, 주입 기술, 개별화된 투여 프로토콜이 애디슨병 관리를 어떻게 변화시키고 있는가?

기존의 애디슨병 치료는 평생에 걸친 호르몬 보충 요법이 필요했습니다. 코르티솔은 보통 하이드로코르티손, 프레드니손, 덱사메타손과 같은 경구용 글루코코르티코이드로 보충되며, 하루 2-3회 투여하여 자연적 일주기 리듬을 모방합니다. 알도스테론 결핍증에는 플루드로코르티손 아세테이트가 사용됩니다.

새로운 치료법은 코티솔 분비의 생리적 모방을 개선하는 데 초점을 맞추었습니다. 하루 종일 보다 안정적인 코티솔 수치를 제공하기 위해 서방형 하이드로코르티손 제제 및 휴대용 펌프를 이용한 하이드로코르티손 지속적 피하주사(CSHI)가 개발되고 있습니다. 이러한 접근법은 투여 횟수를 줄이고 기존 치료에서 발생하는 피크와 트로프를 최소화하는 것을 목표로 합니다.

PULSES 연구와 같은 임상시험에서 CSHI가 환자의 행복감, 에너지 수준, 전반적인 삶의 질을 유의하게 개선하는 것으로 입증되었습니다. 환자들은 기존 경구 투여보다 수액 요법을 선호하며, 더 나은 증상 조절과 피로감 감소를 이유로 꼽았습니다.

첨단 애디슨병 치료제 수요를 주도하는 환자군, 임상현장, 지역 시장은?

애디슨병은 미국에서 약 10만 명 중 1명이 앓고 있는 희귀질환이지만, 중년 여성이나 다른 자가면역질환을 앓고 있는 환자 등 특정 집단이 발병하기 쉽습니다. 효과적인 관리 전략의 필요성은 이러한 집단과 치료를 복잡하게 만드는 동반 질환을 가진 환자에서 특히 심각합니다.

북미와 유럽의 의료 시스템은 탄탄한 의료 인프라와 보험 상환 프레임워크에 힘입어 첨단 치료법을 채택하는 데 앞장서고 있습니다. 반면, 아시아, 아프리카, 라틴아메리카의 많은 지역에서는 전문 치료법에 대한 접근성이 여전히 제한되어 있으며, 의료 격차를 해소하기 위한 세계 보건 구상의 필요성이 강조되고 있습니다.

애디슨병 치료제는 호르몬 대체요법, 환자 중심 치료, 희귀질환 연구 등 다양한 맥락에서 어떤 전략적 역할을 할 수 있는가?

애디슨병 치료제의 발전은 내분비학 분야에서 맞춤형 의료와 환자 중심 치료로의 전환을 보여주는 사례입니다. 치료 요법을 환자 개개인의 필요에 맞게 조정하고, 자연 호르몬 패턴에 충실하게 재현하는 기술을 활용함으로써 임상의는 치료 결과를 개선하고 환자의 삶의 질을 향상시킬 수 있습니다.

또한 애디슨병에 대한 연구는 자가면역질환과 호르몬 대체요법에 대한 폭넓은 이해에 기여합니다. 이 질환의 관리에서 얻은 지식은 다른 부신 기능 부전 및 내분비 질환의 치료 접근법에 반영되어 이 분야 전반의 기술 혁신을 촉진할 것입니다.

헬스케어가 더욱 개인화되고 기술적으로 통합된 모델로 계속 진화하는 가운데, 애디슨병 관리의 혁신이 다른 희귀질환과 만성질환의 치료를 발전시킬 수 있는 청사진이 될 수 있는가?

부문

치료(경구약, 비경구약); 최종 사용(병원·진료소 최종 사용, 진단 실험실 최종 사용)

조사 대상 기업의 예(총 47건)

  • Alexion Pharmaceuticals
  • Amryt Pharma
  • AstraZeneca
  • BioMarin Pharmaceutical
  • Bristol-Myers Squibb
  • Chiasma
  • Ferring Pharmaceuticals
  • HRA Pharma
  • Horizon Therapeutics
  • Ipsen
  • Mallinckrodt Pharmaceuticals
  • Mylan(now part of Viatris)
  • Novartis
  • Novo Nordisk
  • Perrigo Company
  • Pfizer
  • Recordati
  • Sanofi
  • Shire(part of Takeda)
  • Teva Pharmaceutical

AI 통합

당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.07.04

Global Addison's Disease Therapeutics Market to Reach US$948.3 Million by 2030

The global market for Addison's Disease Therapeutics estimated at US$681.4 Million in the year 2024, is expected to reach US$948.3 Million by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Oral Drugs, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$661.4 Million by the end of the analysis period. Growth in the Parenteral Drugs segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$185.7 Million While China is Forecast to Grow at 9.1% CAGR

The Addison's Disease Therapeutics market in the U.S. is estimated at US$185.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$193.2 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Addison’s Disease Therapeutics Market - Key Trends & Drivers Summarized

Why Are Addison’s Disease Therapeutics Gaining Strategic Importance Across Endocrinology, Rare Disease Management, and Hormone Replacement Innovation?

Addison’s disease, or primary adrenal insufficiency, is a rare endocrine disorder characterized by the adrenal glands' inability to produce sufficient cortisol and, in many cases, aldosterone. This hormonal deficiency can lead to symptoms such as fatigue, weight loss, low blood pressure, and hyperpigmentation. Without appropriate treatment, patients are at risk of life-threatening adrenal crises, especially during periods of stress or illness .

The increasing recognition of Addison’s disease's impact on patient quality of life and the potential for severe complications has underscored the need for effective therapeutic strategies. Advances in diagnostic techniques have improved early detection, while ongoing research into hormone replacement therapies aims to better mimic natural hormonal rhythms, thereby enhancing patient outcomes.

How Are Modified-Release Formulations, Infusion Technologies, and Personalized Dosing Protocols Transforming Addison’s Disease Management?

Traditional treatment for Addison’s disease involves lifelong hormone replacement therapy. Cortisol is typically replaced with oral glucocorticoids such as hydrocortisone, prednisone, or dexamethasone, administered two to three times daily to simulate natural circadian rhythms. Aldosterone deficiency is managed with fludrocortisone acetate .

Emerging therapies focus on improving the physiological mimicry of cortisol secretion. Modified-release hydrocortisone formulations and continuous subcutaneous hydrocortisone infusion (CSHI) via portable pumps have been developed to provide more stable cortisol levels throughout the day. These approaches aim to reduce the frequency of dosing and minimize peaks and troughs associated with conventional therapy .

Clinical trials, such as the PULSES study, have demonstrated that CSHI can significantly improve patient well-being, energy levels, and overall quality of life. Patients reported a preference for infusion therapy over traditional oral dosing, citing better symptom control and reduced fatigue .

Which Patient Populations, Clinical Settings, and Regional Markets Are Driving Demand for Advanced Addison’s Disease Therapeutics?

While Addison’s disease is rare, affecting approximately 1 in 100,000 individuals in the U.S., certain populations are more susceptible, including middle-aged women and individuals with other autoimmune conditions. The need for effective management strategies is particularly acute in these groups, as well as in patients with comorbidities that complicate treatment .

Healthcare systems in North America and Europe are at the forefront of adopting advanced therapies, supported by robust healthcare infrastructure and reimbursement frameworks. In contrast, access to specialized treatments remains limited in many parts of Asia, Africa, and Latin America, highlighting the need for global health initiatives to address disparities in care.

What Strategic Role Will Addison’s Disease Therapeutics Play in the Broader Context of Hormone Replacement Therapy, Patient-Centered Care, and Rare Disease Research?

Advancements in Addison’s disease therapeutics exemplify the shift toward personalized medicine and patient-centered care in endocrinology. By tailoring treatment regimens to individual patient needs and leveraging technologies that closely replicate natural hormone patterns, clinicians can improve outcomes and enhance quality of life for those affected.

Furthermore, research into Addison’s disease contributes to the broader understanding of autoimmune disorders and hormone replacement therapy. Insights gained from managing this condition can inform treatment approaches for other forms of adrenal insufficiency and endocrine disorders, fostering innovation across the field.

As healthcare continues to evolve toward more individualized and technologically integrated models, could the innovations in Addison’s disease management serve as a blueprint for advancing care in other rare and chronic conditions?

SCOPE OF STUDY:

The report analyzes the Addison's Disease Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Oral Drugs, Parenteral Drugs); End-Use (Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • Alexion Pharmaceuticals
  • Amryt Pharma
  • AstraZeneca
  • BioMarin Pharmaceutical
  • Bristol-Myers Squibb
  • Chiasma
  • Ferring Pharmaceuticals
  • HRA Pharma
  • Horizon Therapeutics
  • Ipsen
  • Mallinckrodt Pharmaceuticals
  • Mylan (now part of Viatris)
  • Novartis
  • Novo Nordisk
  • Perrigo Company
  • Pfizer
  • Recordati
  • Sanofi
  • Shire (part of Takeda)
  • Teva Pharmaceutical

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Addison's Disease Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Adrenal Insufficiency Conditions Throws the Spotlight on Addisons Disease Therapeutics
    • Growth in Autoimmune Disorder Diagnosis Drives Targeted Hormone Replacement Therapy Use
    • Increased Demand for Injectable Crisis Medication Supports Emergency Preparedness in Patients
    • Integration of Digital Health Platforms for Dose Management Enhances Patient Monitoring
    • Expansion of Personalized Dosing Algorithms Promotes Individualized Hormone Balancing
    • OEMs Offering Hydrocortisone Delivery Devices Improve Self-Administration Accuracy
    • Education Campaigns and Endocrinology Awareness Boost Early Diagnosis and Adherence
    • Growth in Pediatric and Geriatric Patient Segments Spurs Age-Specific Formulations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Addison's Disease Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Addison's Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Addison's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Oral Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Parenteral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Parenteral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Parenteral Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Addison's Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Addison's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Addison's Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Addison's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: India 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Addison's Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Addison's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Addison's Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Addison's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제